PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.

[1]  Á. Lanas,et al.  Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation , 2013, Thrombosis and Haemostasis.

[2]  M. V. van Oijen,et al.  Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care , 2013, BMJ Open.

[3]  P. Miner,et al.  Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric‐coated aspirin 325 mg + immediate‐release omeprazole 40 mg) or enteric‐coated aspirin 325 mg + enteric‐coated omeprazole 40 mg – a randomised, phase 1, crossover study , 2013, Alimentary pharmacology & therapeutics.

[4]  A. Shuldiner,et al.  Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. , 2013, American heart journal.

[5]  E. Elkin,et al.  Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management , 2013, American Journal of Cardiovascular Drugs.

[6]  T. Andersson,et al.  Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. , 2012, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[7]  D. Wald,et al.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. , 2012, The American journal of medicine.

[8]  Deepak L. Bhatt,et al.  Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review , 2012, Heart.

[9]  T. Joh,et al.  Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin , 2011, Scandinavian journal of gastroenterology.

[10]  L. Køber,et al.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study , 2011, BMJ : British Medical Journal.

[11]  Á. Lanas,et al.  Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON) , 2011, Heart.

[12]  Charles J. Kahi,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.

[13]  Deepak L. Bhatt,et al.  Clopidogrel with or without omeprazole in coronary artery disease. , 2010, The New England journal of medicine.

[14]  C. O'connor,et al.  Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. , 2010, American heart journal.

[15]  Deepak L. Bhatt,et al.  Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). , 2010, The American journal of cardiology.

[16]  C. Hawkey,et al.  Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin , 2008, The American Journal of Gastroenterology.

[17]  I. Wiklund,et al.  Validation of a four-graded scale for severity of heartburn in patients with symptoms of gastroesophageal reflux disease. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  Kevin E. Kip,et al.  The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.

[19]  B. Hunt,et al.  Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  F. Chan,et al.  Drug-induced side effects affecting the gastrointestinal tract , 2006, Expert opinion on drug safety.

[21]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[22]  W. Dodge,et al.  The impact of low‐dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non‐selective non‐steroidal anti‐inflammatory drug or a cyclo‐oxygenase‐2‐selective inhibitor , 2006, Alimentary pharmacology & therapeutics.

[23]  L. Laine,et al.  Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. , 2004, Gastroenterology.

[24]  K. Fox,et al.  Coronary disease MANAGEMENT OF ACUTE CORONARY SYNDROMES : AN UPDATE Keith A A Fox , 2004 .

[25]  H. Souza,et al.  Upper gastrointestinal bleeding in a Brazilian hospital: a retrospective study of endoscopic records. , 2002, Arquivos de gastroenterologia.

[26]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[27]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[28]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.

[29]  G. Tytgat,et al.  Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. , 1997, The American journal of gastroenterology.

[30]  M. Bottai,et al.  Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  N. Harte,et al.  Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid , 2011, The patient.

[32]  U. Fuhr,et al.  Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH , 2008, European Journal of Clinical Pharmacology.